Statement of Deviation & Variation as on June 30, 2026
Statement of Deviation and Variation for Q1 ended June 30, 2026
- No deviation in IPO proceeds utilization from objects stated in prospectus
- Variation approved by shareholders via postal ballot on April 25, 2026
- Audit committee and auditors gave no comments on deviation
- Fund utilization details: Rs 77 Cr for Parekh Hospital acquisition fully utilized
- Rs 25.15 Cr variation in capital expenditure for new hospital setup
- Rs 12.62 Cr variation in funding inorganic growth through acquisitions
- Rs 0.42 Cr variation in issue expenses
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 GKSL — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add GKSL to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Gujarat Kidney And Super Speciality Limited
Important.
The summary above is generated automatically from Gujarat Kidney And Super Speciality Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.